Aurora Kinase A Inhibition and Paclitaxel As Targeted Combination Therapy for Head and Neck Squamous Cell Carcinoma

Overview

Journal Head Neck

Specialties General Surgery
Oncology

Date 2008 Dec 25

PMID 19107951

Citations 36

Authors

Abhijit Mazumdar

Ying C Henderson

Adel K El-Naggar

Subrata Sen

Gary L Clayman

Affiliations

Soon will be listed here.

Abstract

Background: Aurora kinase A (AURKA) is amplified with varying incidence in multiple human cancers including head and neck squamous cell carcinoma (HNSCC). We investigated whether AURKA is a potential therapeutic target in HNSCC.

Methods: We conducted an immunohistochemical analysis of AURKA expression in paired normal and tumor samples (n = 63). HNSCC cells treated with siRNA specific for AURKA were assessed for AURKA mRNA and protein expression levels by reverse transcriptase-polymerase chain reaction and Western blot analysis. Tumor cells treated with siRNA and paclitaxel were assessed for cell proliferation by MTT assay and for cell cycle distribution by flow cytometry.

Results: AURKA expression was higher in tumor than in adjacent normal in most (85%) of the samples analyzed. HNSCC cells and primary tumors revealed high expression levels of AURKA. Most primary tumors also showed high kinase activity of the enzyme. Targeted AURKA inhibition increased the sub-G1 cell fraction, with a concomitant reduction in the G1 cell population, indicating induction of apoptosis and thus markedly suppressed proliferation of HNSCC cells. Combining siRNA-induced AURKA inhibition with 5 to 10 nM paclitaxel synergistically enhanced apoptosis induction.

Conclusion: AURKA is a potential therapeutic target for HNSCC. Further investigation of small-molecule AURKA inhibitors as therapeutic agents is warranted.

Citing Articles

Aurora kinase A expression in pleomorphic adenoma, adenoid cystic carcinoma, and mucoepidermoid carcinoma of salivary glands: an immunohistochemical study.

Zare R, Izadi L, Alarcon-Sanchez M, Taghva M, Ranjbar M BMC Oral Health. 2025; 25(1):89.

PMID: 39825351 PMC: 11740330. DOI: 10.1186/s12903-024-05276-5.

Caspase-mediated AURKA cleavage at Asp is essential for paclitaxel to elicit cell apoptosis.

Chen X, Du S, Zhang Y, Peng K, Liu L, Wang T Theranostics. 2024; 14(10):3909-3926.

PMID: 38994036 PMC: 11234276. DOI: 10.7150/thno.97842.

Aurora Kinases as Therapeutic Targets in Head and Neck Cancer.

Nguyen T, Silva F, Golemis E Cancer J. 2022; 28(5):387-400.

PMID: 36165728 PMC: 9836054. DOI: 10.1097/PPO.0000000000000614.

Population Pharmacokinetics and Exposure-Safety Relationships of Alisertib in Children and Adolescents With Advanced Malignancies.

Zhou X, Mould D, Yuan Y, Fox E, Greengard E, Faller D J Clin Pharmacol. 2021; 62(2):206-219.

PMID: 34435684 PMC: 9274904. DOI: 10.1002/jcph.1958.

Targeted Treatment of Head and Neck (Pre)Cancer: Preclinical Target Identification and Development of Novel Therapeutic Applications.

van Harten A, Brakenhoff R Cancers (Basel). 2021; 13(11).

PMID: 34204886 PMC: 8199752. DOI: 10.3390/cancers13112774.

References

Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun M . Cancer statistics, 2003. CA Cancer J Clin. 2003; 53(1):5-26. DOI: 10.3322/canjclin.53.1.5. View

Miyoshi Y, Iwao K, Egawa C, Noguchi S . Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers. Int J Cancer. 2001; 92(3):370-3. DOI: 10.1002/ijc.1200. View

Anand S, Penrhyn-Lowe S, Venkitaraman A . AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell. 2003; 3(1):51-62. DOI: 10.1016/s1535-6108(02)00235-0. View

Bockmuhl U, Schluns K, Schmidt S, Matthias S, Petersen I . Chromosomal alterations during metastasis formation of head and neck squamous cell carcinoma. Genes Chromosomes Cancer. 2001; 33(1):29-35. View

Li D, Zhu J, Firozi P, Abbruzzese J, Evans D, Cleary K . Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res. 2003; 9(3):991-7. View

Reiter R, Gais P, Jutting U, Steuer-Vogt M, Pickhard A, Bink K . Aurora kinase A messenger RNA overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma. Clin Cancer Res. 2006; 12(17):5136-41. DOI: 10.1158/1078-0432.CCR-05-1650. View

Groisman I, Jung M, Sarkissian M, Cao Q, Richter J . Translational control of the embryonic cell cycle. Cell. 2002; 109(4):473-83. DOI: 10.1016/s0092-8674(02)00733-x. View

Bergnes G, Brejc K, Belmont L . Mitotic kinesins: prospects for antimitotic drug discovery. Curr Top Med Chem. 2005; 5(2):127-45. DOI: 10.2174/1568026053507697. View

Zhou H, Kuang J, Zhong L, Kuo W, Gray J, Sahin A . Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet. 1998; 20(2):189-93. DOI: 10.1038/2496. View

10.

Neben K, Korshunov A, Benner A, Wrobel G, Hahn M, Kokocinski F . Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. Cancer Res. 2004; 64(9):3103-11. DOI: 10.1158/0008-5472.can-03-3968. View

11.

Vokes E, Weichselbaum R, Lippman S, Hong W . Head and neck cancer. N Engl J Med. 1993; 328(3):184-94. DOI: 10.1056/NEJM199301213280306. View

12.

Sen S, Zhou H, White R . A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines. Oncogene. 1997; 14(18):2195-200. DOI: 10.1038/sj.onc.1201065. View

13.

Huang Q, Yu G, McCormick S, Mo J, Datta B, Mahimkar M . Genetic differences detected by comparative genomic hybridization in head and neck squamous cell carcinomas from different tumor sites: construction of oncogenetic trees for tumor progression. Genes Chromosomes Cancer. 2002; 34(2):224-33. DOI: 10.1002/gcc.10062. View

14.

Gritsko T, Coppola D, Paciga J, Yang L, Sun M, Shelley S . Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin Cancer Res. 2003; 9(4):1420-6. View

15.

Yang H, He L, Kruk P, Nicosia S, Cheng J . Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells. Int J Cancer. 2006; 119(10):2304-12. DOI: 10.1002/ijc.22154. View

16.

Kinoshita K, Noetzel T, Pelletier L, Mechtler K, Drechsel D, Schwager A . Aurora A phosphorylation of TACC3/maskin is required for centrosome-dependent microtubule assembly in mitosis. J Cell Biol. 2005; 170(7):1047-55. PMC: 2171544. DOI: 10.1083/jcb.200503023. View

17.

Goepfert T, Adigun Y, Zhong L, Gay J, Medina D, Brinkley W . Centrosome amplification and overexpression of aurora A are early events in rat mammary carcinogenesis. Cancer Res. 2002; 62(14):4115-22. View

18.

Katayama H, Sasai K, Kawai H, Yuan Z, Bondaruk J, Suzuki F . Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet. 2004; 36(1):55-62. DOI: 10.1038/ng1279. View

19.

Jemal A, Murray T, Ward E, Samuels A, Tiwari R, Ghafoor A . Cancer statistics, 2005. CA Cancer J Clin. 2005; 55(1):10-30. DOI: 10.3322/canjclin.55.1.10. View

20.

Sakakura C, Hagiwara A, Yasuoka R, Fujita Y, Nakanishi M, Masuda K . Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation. Br J Cancer. 2001; 84(6):824-31. PMC: 2363814. DOI: 10.1054/bjoc.2000.1684. View